Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market 2021-2027: Industry Analysis, Trends, Growth, Opportunities, and Forecast

The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.5% over the forecast period (2020-2026). The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is sectioned on the basis of drug type. The market is sectioned as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the global dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin and Saxagliptin are projected to hold the most lucrative share in the market. The key aspects that drive the segmental growth of the dipeptidyl peptidase 4 (DPP-4) inhibitors market include the effectiveness of the drugs. As per the NCBI NLM, the Sitagliptin and Saxagliptin drugs hold the lucrative share in the market owing to their effectiveness on the patients.

(Get 15% Discount on Buying this Report)

Get Report Sample Copy @ https://www.omrglobal.com/request-sample/dipeptidyl-peptidase-4-inhibitors-market

There has been an upsurge witnessed in the prevalence of diabetes across the globe. As per the WHO, over the last three decades there has been an upsurge in the prevalence of diabetes. As per the IDF, the cases of diabetic were nearly 463 million across the globe in 2019. The cases are projected to increase which is expected to rise to 578 million by 2030 and nearly 700 million by 2045. An increase in the prevalence of diabetes is likely to demand the proper drugs for the treatment. Thus, owing to the market is likely to witness an upsurge over the forecast period.

A Full Report of Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/dipeptidyl-peptidase-4-inhibitors-market

Market Coverage

Market number available for – 2019-2026
Base year- 2019
Forecast period- 2020-2026
Segment Covered- By Type
Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
Competitive Landscape- Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others

Global Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation

By Type

Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Gemigliptin
Anagliptin
Teneligliptin
Others

Global Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation by Region

North America

United States
Canada

Europe

UK
Germany
Italy
Spain
France
Rest of Europe

Asia-Pacific

China
India
Japan
South Korea
Rest of Asia-Pacific

Rest of the World

Reasons to Buying From us –

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/dipeptidyl-peptidase-4-inhibitors-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.